Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

CADL Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Candel Therapeutics, Inc.NASDAQ: CADL

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables remains negative

Q1 FY2026 net receivables was $0, compared with $0 a year earlier.

Context

  • Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Net receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Net Receivables vs competitors

How CADL compares with its peers on the latest reported figures

  • CADL's Mar 2026 net receivables of $0 is the 6th highest of the 10 companies compared; the peer median is $256.33K.
  • Net receivables amounts to 0.0% of total assets for CADL, versus a peer median of 0.7%.
CADL Competitors Peer median
Net Receivables for CADL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IOVAIovance Biotherapeutics, Inc.Sep 2026$106.99M +60.3%—10.8%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$60.69M +182.5%+158.8%12.8%
PBYIPuma Biotechnology, Inc.Mar 2026$26.33M +4.6%+8.3%13.7%
MGNXMacroGenics, Inc.Mar 2026$10.43M -1.1%-38.0%4.8%
NBPNovaBridge BiosciencesDec 2025$256.33K -97.0%-62.4%0.7%
CADLCandel Therapeutics, Inc.Mar 2026$0 ——0.0%
ORICORIC Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
IMMXImmix Biopharma, Inc.Mar 2026$0 ——0.0%
IPSCCentury Therapeutics, Inc.Mar 2026$0 -100.0%-5.1%0.0%
GNLXGenelux CorporationMar 2026$0 ——0.0%
Peer median (excluding CADL) $256.33K+1.7%-5.1%0.7%

Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents82.64M70.06M35.41M102.65M119.73M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets2.3M1.89M1.38M00
Total Current Assets84.95M71.95M36.8M103.8M119.73M
Property, Plant & Equipment (Net)3.84M5.48M4.02M2.73M0
Goodwill00000
Intangible Assets00000
Long-term Investments424K266K00416K
Tax Assets0828K000
Other Non-current Assets00382K329K5.05M
Total Non-current Assets4.26M6.57M4.4M3.06M5.46M
Total Assets89.21M78.52M41.2M106.87M125.2M
Account Payables1.59M380K422K237K1.13M
Short-term Debt0464K8.89M9.9M445K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.68M2.12M2.34M22.11M7.42M
Total Current Liabilities5.36M5.62M14.18M37.53M9M
Long-term Debt560K20.85M12.38M2.6M1.46M
Deferred Tax Liabilities0828K000
Deferred Revenue (Non-current)0144K000
Other Non-current Liabilities19.15M1.88M916K062.82M
Total Non-current Liabilities19.71M25.19M14.27M3.01M64.28M
Total Liabilities25.07M30.81M28.46M40.54M73.27M
Common Stock286K290K290K469K550K
Retained Earnings(80.3M)(99.09M)(137.03M)(192.21M)(230.39M)
Accumulated OCI(89.21M)00(0)0
Other Stockholders Equity00000
Minority Interest00000
Total Equity64.14M47.71M12.75M66.33M51.92M
Total Debt560K22.8M22.76M13.47M1.9M
Net Debt(82.08M)(47.26M)(12.65M)(89.18M)(117.83M)

Candel Therapeutics, Inc.

NASDAQ:CADL

Intrinsic Alpha fair value

Locked

Current Price

$5.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.